Cytokine-suppressive anti-inflammatory drugs (CSAIDs) inhibit invasion and MMP-1 production of ovarian carcinoma cells

被引:18
作者
Denkert, C [1 ]
Koch, I [1 ]
Berger, S [1 ]
Köbel, M [1 ]
Siegert, A [1 ]
Hauptmann, S [1 ]
机构
[1] Charite Hosp, Inst Pathol, D-10117 Berlin, Germany
关键词
ovarian carcinoma; invasion; matrix metalloproteinases;
D O I
10.1016/S0304-3835(03)00052-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The development of therapeutic strategies for inhibition of peritoneal dissemination and invasion would be central for the treatment of ovarian carcinoma. In the microenvironment of ovarian carcinomas, various inflammatory cytokines like tumor necrosis factor alpha (TNF-alpha) are present. In this study we investigated the role of inflammatory cytokines in the regulation of invasion of SKOV-3 ovarian carcinoma cells in-vitro. Treatment of cells with TNF-alpha or interleukin 1beta (IL-1beta) lead to increased phosphorylation of the stress-activated p38 mitogen-activated protein kinase (p38MAPK). Furthermore, TNF-alpha as well as IL-1beta stimulated matrigel invasion of tumor cells. An inhibitor of stress-activated protein kinase pathways, the cytokine- suppressive anti-inflammatory drug (CSAID) SB203580 inhibited invasion of cytokine-stimulated SKOV-3 cells. The MEK-1 inhibitor PD98059 similarly inhibited invasion of cytokine-stimulated cells, but to a lesser extent. Expression of mRNA and protein levels of matrix metalloproteinase-1 (MMP-1) by SKOV-3 cells could be stimulated by inflammatory cytokines and inhibited by S13203580, and partially also by PD98059. Our results show that CSAIDs reduce invasion and MMP expression of ovarian carcinoma cells. Further studies are required to investigate whether inhibition of cytokine-induced signal transduction may be of value in therapy of ovarian carcinomas in-vivo. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:101 / 109
页数:9
相关论文
共 31 条
  • [1] Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453
  • [2] The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis in response to tumour necrosis factor
    Beyaert, R
    Cuenda, A
    VandenBerghe, W
    Plaisance, S
    Lee, JC
    Haegeman, G
    Cohen, P
    Fiers, W
    [J]. EMBO JOURNAL, 1996, 15 (08) : 1914 - 1923
  • [3] Boström PJ, 2000, INT J CANCER, V88, P417, DOI 10.1002/1097-0215(20001101)88:3<417::AID-IJC14>3.3.CO
  • [4] 2-7
  • [5] Independent role of p38 and ERK1/2 mitogen-activated kinases in the upregulation of matrix metalloproteinase-1
    Brauchle, M
    Glück, D
    Di Padova, F
    Han, JH
    Gram, H
    [J]. EXPERIMENTAL CELL RESEARCH, 2000, 258 (01) : 135 - 144
  • [6] The p38-MAPK inhibitor, SB203580, inhibits cardiac stress-activated protein kinases/c-Jun N-terminal kinases (SAPKs/JNKs)
    Clerk, A
    Sugden, PH
    [J]. FEBS LETTERS, 1998, 426 (01) : 93 - 96
  • [7] SB-203580 IS A SPECIFIC INHIBITOR OF A MAP KINASE HOMOLOG WHICH IS STIMULATED BY CELLULAR STRESSES AND INTERLEUKIN-1
    CUENDA, A
    ROUSE, J
    DOZA, YN
    MEIER, R
    COHEN, P
    GALLAGHER, TF
    YOUNG, PR
    LEE, JC
    [J]. FEBS LETTERS, 1995, 364 (02) : 229 - 233
  • [8] Specificity and mechanism of action of some commonly used protein kinase inhibitors
    Davies, SP
    Reddy, H
    Caivano, M
    Cohen, P
    [J]. BIOCHEMICAL JOURNAL, 2000, 351 (351) : 95 - 105
  • [9] Ellerbroek SM, 2001, CANCER RES, V61, P1855
  • [10] Fogh J., 1975, HUMAN TUMOR CELLS IN, P115, DOI DOI 10.1007/978-1-4757-1647-4_5